SLC5A2 and type 2 diabetes mellitus: Especially in recent years, the broader use of sodium–glucose cotransporter 2 (SGLT2) inhibitors has raised awareness of DKA in type 2 diabetes, since this modern antidiabetic drug class precipitates euglycemic DKA (6).